US · CYCN
Cyclerion Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02142
- Website
- cyclerion.com
Price · as of 2024-12-31
$3.26
Market cap 5.14M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $29,656.88 | +909,620.25% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $73.40 | ||||
| 2020 | $85.40 | $90.52 | $0.00 | $0.00 | $1,982.69 |
| 2021 | $19.80 | $254.16 | $0.00 | $0.00 | $0.00 |
| 2022 | $12.10 | $16.63 | $0.00 | $0.00 | $1,600.70 |
| 2023 | $3.13 | $244.70 | |||
| 2024 | $2.80 | $2.64 | $0.00 |
AI valuation
Our deep-learning model estimates Cyclerion Therapeutics, Inc.'s (CYCN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $3.26
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$29,656.88
+909,620.25% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CYCN | Cyclerion Therapeutics, I… | $3.26 | 5.14M | — | +909,620% | — | — | -2.31 | 0.80 | 3.53 | -1.05 | — | 0.80 | 100.00% | -181.40% | -152.85% | -30.36% | -77.73% | -26.64% | 0.00 | — | 5.83 | 5.22 | 0.89 | -8654.00% | — | -7960.00% | -61.46% | -5.98 | -92.83% | 0.00% | 0.00% | 0.00% | -1.05 | -0.88 | 1.91 | -33.88 |
| ADXN | Addex Therapeutics Ltd | $7.28 | 4.81M | +9,333% | +38% | +845% | — | 0.71 | 0.52 | 12.45 | -0.37 | — | 0.52 | 100.00% | -681.82% | 1746.04% | 130.39% | -137.95% | 92.11% | 0.00 | -776.78 | 4.42 | 4.19 | 0.71 | -15000.00% | -7495.00% | -3281.00% | -106.85% | -6.70 | -269.11% | 0.00% | 0.00% | 0.00% | -0.63 | -0.32 | 4.27 | -43.82 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| PLRZ | Polyrizon Ltd. | $12.49 | 13.01M | — | — | — | — | -8.81 | 2.58 | — | -7.77 | — | 5.67 | 0.00% | — | — | -57.83% | -88.33% | -50.61% | 0.00 | -434.00 | 10.16 | 9.79 | 1.79 | — | — | 11359.00% | -8.43% | -4.39 | -77.82% | 0.00% | 0.00% | 20.20% | -8.49 | -9.64 | — | 29.76 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| RADX | Radiopharm Theranostics L… | $4.99 | 6.43M | +1,761% | — | — | — | — | 1.36 | 16.76 | -0.83 | — | -34.17 | 1.08% | -1050.63% | -1055.27% | 0.00% | -302.69% | 0.00% | 0.00 | -584.59 | 2.67 | 2.65 | 0.76 | -8533.00% | 111427.00% | 5950.00% | -60.17% | -2.45 | -290.58% | 0.00% | — | 17.31% | -0.83 | -0.87 | 8.75 | -2.59 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
| XTLB | XTL Biopharmaceuticals Lt… | $0.76 | 1.04M | — | +76% | — | — | -2.05 | 0.39 | 4.66 | -1.18 | — | -1.34 | 0.67% | -481.60% | -227.72% | -26.83% | -83.03% | -18.71% | 0.03 | -25.26 | 0.61 | 0.56 | 0.25 | — | — | 13649.00% | -79.50% | -0.73 | -72.01% | 0.00% | 0.00% | 0.00% | -0.51 | -0.66 | 2.44 | -26.54 |
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- CEO
- Regina Graul
- Employees
- 1
- Beta
- 0.95
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($29,656.88 ÷ $3.26) − 1 = +909,620.25% (DCF, example).